Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Weight loss products (4)
- Advertising (222)
- Regulatory compliance (96)
- Prescription medicines (64)
- COVID-19 (50)
- Therapeutic goods regulation (43)
- Medicine safety (27)
- Vaping hub (26)
- Compliance and enforcement hub (22)
- Medicinal cannabis hub (17)
- Import and export (15)
- COVID-19 vaccines (13)
- Medical devices safety (12)
- Scheduling (national classification system) (12)
- Manufacturing (9)
- Complementary medicines (8)
- Listed medicines (8)
- Australian Register of Therapeutic Goods (ARTG) (7)
- Safety (7)
- Legislation (6)
- Non-prescription medicines (6)
- Over the counter (OTC) medicines (5)
- Alert/Advisory (4)
- Labelling and packaging (4)
- Shortages (4)
- Cosmetics (2)
- In Vitro Diagnostic medical devices (IVDs) (2)
- Prescription opioids hub (2)
- Advisory bodies and committees (1)
- Assessed listed medicines (1)
- Fees and payments (1)
- Sunscreens (1)
- Travelling with health products (1)
- Unique Device Identification (UDI) hub (1)
Search
4 result(s) found, displaying 1 to 4
-
Media releasesWe have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
Media releasesThe TGA reminds businesses and media outlets that it is unlawful to publicly advertise prescription-only medicines, including prescription-only weight loss medicines.
-
Media releasesAmendments to the Therapeutic Goods Regulations 1990 (Schedule 5, item 6) have been made resulting in compounded GLP-1 RA products no longer being able to be compounded by pharmacists and supplied to patients.
-
Media releasesThe TGA is aware of several scams targeting consumers seeking semaglutide (Ozempic). Consumers are strongly advised not to use products unless they have come from a trusted source.